Development of recommendations for dosing of commonly prescribed medications in critically ill obese children

Emma L Ross1, Justin Heizer2, Mark A Mixon2

  • 1Emma L. Ross, Pharm.D., is Pediatric Clinical Pharmacist, American Family Children's Hospital, UW Hospital and Clinics, Madison, WI; at the time of writing she was Pharmacy Practice Resident, Department of Pharmacy, Children's Hospital Colorado, Aurora. Justin Heizer, Pharm.D., is Postgraduate Year 1 Pharmacy Practice Resident; and Mark A. Mixon, Pharm.D., is Postgraduate Year 1 Pharmacy Practice Resident, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado (UC), Aurora. Jennifer Jorgensen, Pharm.D., is Clinical Pharmacist, General Medicine, Department of Pharmacy, Children's Hospital Colorado. Connie A. Valdez, Pharm.D., M.S.Ed., BCPS, is Associate Professor, Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC. Angela S. Czaja, M.D., M.Sc., is Associate Professor and Associate Fellowship Director, Division of Critical Care, Department of Pediatrics, School of Medicine, and Center for Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC. Pamela D. Reiter, Pharm.D., is Clinical Pharmacy Specialist, Pediatric Intensive Unit, Department of Pharmacy, Children's Hospital Colorado, and Clinical Associate Professor of Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC. emma.ross@childrenscolorado.org.

Insights

Limited data exists for medication dosing in critically ill obese children. A decision support tool was developed to guide dosing weight recommendations, improving medication safety for this vulnerable population.

Area of Science:

  • Pediatric critical care medicine
  • Pharmacology
  • Clinical decision support systems

Background:

  • Dosing critically ill obese children presents unique challenges due to altered pharmacokinetics.
  • Existing literature on medication dosing for pediatric obesity is scarce and often lacks pediatric-specific data.

Purpose of the Study:

  • To develop and implement a decision support tool for formulating medication dosing recommendations in critically ill obese children.
  • To address the inadequacy of existing obesity dosing information for pediatric intensive care unit (PICU) patients.

Main Methods:

  • Identified commonly prescribed medications in critically ill children from the Pediatric Health Information System.
  • Conducted a systematic literature search for obesity dosing evidence using PubMed and Ovid.
  • Developed a usefulness scoring system and decision support tool integrating pharmacokinetic data and clinical considerations.

Main Results:

  • Evaluated 113 medications, reviewing 122 citations; only 13% contained pediatric-specific obesity dosing information.
  • The decision support tool recommended total body weight for 52 medications, adjusted weight for 43, and ideal body weight for 18.
  • A mean usefulness score of 5.1 (median 7) indicated variable literature quality and applicability.

Conclusions:

  • The lack of robust evidence necessitates a structured approach to pediatric obesity medication dosing.
  • The developed decision support tool aids clinicians in making evidence-informed dosing weight recommendations for obese pediatric patients.
  • This tool enhances the safe and effective use of medications in a critical care setting for children with obesity.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
349
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
896
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
413
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
505
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
851